Neoadjuvant prehabilitation to improve physical and mental recovery for people with solid tumors
Official title: Effects of Neoadjuvant Prehabilitation on Post-Interventional Physical and Psychological Outcomes in Oncology Patients With Solid Tumors: A Prospective, Two-arm, Controlled, Monocentric Interventional Study
Run by University Hospital Muenster · NCT07464457 · Data updated 2026-11-12
This trial tests whether a supervised exercise program plus structured psycho-oncological support before surgery or radiotherapy helps adults with solid tumors stay fitter and feel better than standard care.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 125 (estimated) |
| Sponsor | University Hospital Muenster Academic / other |
| Locations | 1 site (Münster, North Rhine-Westphalia) |
| Status | Recruiting |
| Started | March 2026 |
| Main results expected | August 2029 |
| Study ends | October 2029 |
| Registry record updated | March 11, 2026 |
| Trial ID | NCT07464457 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (over 18) with curative-intent treatment plans for solid tumors (especially breast cancer), ECOG 0–2, able to participate in exercise and complete questionnaires, and able to attend the program at the study site.
✕Probably not a fit
Patients with medical contraindications to physical activity, severe cardiac or pulmonary disease, those who are pregnant or breastfeeding, have acute infections, lack capacity to consent, or are ineligible for curative-intent treatment are unlikely to benefit or to be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
NEOPRO-SIT is a prospective, two-arm, controlled, single-center interventional study enrolling 125 patients with solid tumors, with a focus on breast cancer. Participants receive either usual care (a low-resource consultation-based approach) or a structured, closely supervised prehabilitation program combining targeted exercise therapy and psycho-oncological support during the neoadjuvant period. The trial uses a sequential non-randomized design to compare physical capacity, psychological capacity, and quality of life outcomes between groups. The aim is to create a feasible, standardized prehabilitation concept that can be integrated into routine oncology care if beneficial.
Why it matters
Potential benefit: If successful, the program could improve preoperative fitness, reduce psychological distress, and enhance quality of life and recovery after local cancer treatment.
How similar studies have gone: Similar prehabilitation programs have shown promising improvements in fitness, postoperative outcomes, and quality of life in smaller studies, but broader evidence is still emerging.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with solid tumors (focus on breastcancer) * Curative-intent multimodal treatment concept with local surgical or radiotherapeutic ablation * Working age and \> 18 years * ECOG 0-2 * Sufficient language skills to understand questionnaires/training instructions Exclusion Criteria: * Severe cardiac or pulmonary comorbidities that do not allow participation in the program * Medical contraindications for physical activity * Lack of patient capacity to consent * Pregnancy/breastfeeding * Acute infections/fever * Participation in another clinical intervention study
Where it's running
-
University hospital Münster
Münster, North Rhine-Westphalia, Germany Recruiting
Study contacts
- Principal investigator: Annalen Bleckmann, Univ.-Prof. Dr. med. — University hospital Münster
- Study coordinator: Mira Meyer-Ács
- Email: mira.meyer-acs@ukmuenster.de
- Phone: +49 251 8349134
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
SI-B036 in locally advanced or metastatic breast cancer and other solid tumors
Scientists are testing SI-B036 to see if it is safe and tolerable in adults with advanced breast cancer or other solid tumors and to get early signals of whether it might help.
-
OCT-598 for advanced solid tumors
This trial tests whether OCT-598, by itself or with docetaxel, is safe and to find the best dose for adults with advanced solid tumors who have limited standard treatment options.
-
TER-2013 for advanced solid tumors with AKT/PI3K/PTEN pathway changes
This trial tests whether TER-2013, alone or with fulvestrant, is safe and can help people with advanced breast, ovarian, endometrial, lung, or head-and-neck cancers that have AKT/PI3K/PTEN pathway alterations.
-
Using brodalumab to treat immune-related side effects from cancer therapy
This study is testing if brodalumab can help cancer patients who are having immune-related side effects from their immunotherapy treatment feel better.
-
Imaging study using two antibody fragments in patients with solid tumors
This study is testing two special antibody fragments in people with solid tumors to see how well they target cancer cells and how they move through the body.
-
Evaluating GNC-077 for advanced breast cancer and solid tumors
This study is testing a new drug called GNC-077 to see if it is safe and effective for people with advanced breast cancer and other solid tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.